Difference between revisions of "Part:BBa K2943005"

Line 8: Line 8:
 
1.<b> We created a plasmid which contains prf 15 and prf16:</b><br>
 
1.<b> We created a plasmid which contains prf 15 and prf16:</b><br>
 
We inserted a gblock of prf15 and prf16 into the  backbone vector using Gibson Assembley.<br> Then, We transformed the gibson results into bacteria.  After that we used miniprep kit to extract and sequence the plasmid and confirmed the gibson was successful without mutation.<br>
 
We inserted a gblock of prf15 and prf16 into the  backbone vector using Gibson Assembley.<br> Then, We transformed the gibson results into bacteria.  After that we used miniprep kit to extract and sequence the plasmid and confirmed the gibson was successful without mutation.<br>
In addition, we used IPTG to induce prf 15 and prf16, and run the results through protein gel to make sure they were induced. For control we used bacteria that were not induced by IPTG.<br>
+
In addition, we used IPTG to induce prf 15 and prf16, and run the results through protein gel to make sure they were induced. For control we used bacteria that were not induced by IPTG.<br><br>
[[Image: T--Tau_Israel--PRF15_PRF16_doublepic.png|Middle|400px|Left: Protein gel for induced prf15 and prf 16.Right: Transformation plates for prf15 and prf16]]
+
[[Image: T--Tau_Israel--PRF15_PRF16_doublepic.png|Left|400px|Left: Protein gel for induced prf15 and prf 16.Right: Transformation plates for prf15 and prf16]]
<br>
+
<br><br>
 
2.<b> We have done a plaque assay with the wild type <em>Pseudomonas aeruginosa</em> PAO1:</b><br>
 
2.<b> We have done a plaque assay with the wild type <em>Pseudomonas aeruginosa</em> PAO1:</b><br>
 
Using the plaque assay protocol that can be found here: [insert link to our protocol in prorocols.io], we tested the pyocin system in the WT PAO1. After inducing SOS response in the bacteria with Mitomycin C, we extracted the lysate that contains the pyocin. Then, we pipette the lysate down on a plate that contained the target strains. As control, we used PAO1 that did not receive Mitomycin C and therefore did not undergo SOS response and created pyocin. No target bacteria grew on the area where we pipette the WT's lysate.<br>
 
Using the plaque assay protocol that can be found here: [insert link to our protocol in prorocols.io], we tested the pyocin system in the WT PAO1. After inducing SOS response in the bacteria with Mitomycin C, we extracted the lysate that contains the pyocin. Then, we pipette the lysate down on a plate that contained the target strains. As control, we used PAO1 that did not receive Mitomycin C and therefore did not undergo SOS response and created pyocin. No target bacteria grew on the area where we pipette the WT's lysate.<br>

Revision as of 07:13, 20 October 2019


prf15 and prf16 from Pseudomonas aeruginosa PAO1

Tail fiber protein (prf15) and its' chaperone (prf16) allows Pseudomonas aeruginosa's Pyocin particles to target rival Pseudomonas strains. They act as a homotrimer that forms a tail which connects to the base-plate of the Pyocin on one side, and to the membrane of the rival bacteria on the other. This attachment is the first step in the process of attacking rival bacteria. The tail fiber determines the specific target that can be destroyed and will be only expressed after an SOS response, such as DNA damage.

We have validated the mechanism of the prf15 and prf16 as part of our wet lab work in 2 ways:
1. We created a plasmid which contains prf 15 and prf16:
We inserted a gblock of prf15 and prf16 into the backbone vector using Gibson Assembley.
Then, We transformed the gibson results into bacteria. After that we used miniprep kit to extract and sequence the plasmid and confirmed the gibson was successful without mutation.
In addition, we used IPTG to induce prf 15 and prf16, and run the results through protein gel to make sure they were induced. For control we used bacteria that were not induced by IPTG.

Left: Protein gel for induced prf15 and prf 16.Right: Transformation plates for prf15 and prf16

2. We have done a plaque assay with the wild type Pseudomonas aeruginosa PAO1:
Using the plaque assay protocol that can be found here: [insert link to our protocol in prorocols.io], we tested the pyocin system in the WT PAO1. After inducing SOS response in the bacteria with Mitomycin C, we extracted the lysate that contains the pyocin. Then, we pipette the lysate down on a plate that contained the target strains. As control, we used PAO1 that did not receive Mitomycin C and therefore did not undergo SOS response and created pyocin. No target bacteria grew on the area where we pipette the WT's lysate.
[INSERT PLATE PIC]


Link to the our tail plasmid assembly notebook: https://2019.igem.org/wiki/images/4/48/T--TAU_Israel--Protocols-tails_plasmids_cloning_notebook.pdf

Reference:
[1] Williams, Steven R., et al. "Retargeting R-type pyocins to generate novel bactericidal protein complexes." Appl. Environ. Microbiol. 74.12 (2008): 3868-3876.
[2]Scholl, Dean, et al. "An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen Escherichia coli O157: H7." Antimicrobial agents and chemotherapy 53.7 (2009): 3074-3080.
Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]